August 31, 2020

2020-2021 InterAsma Webinars

2020-2021 InterAsma Webinars

The webinars are one-hour monthly educational events offered monthly from September to June each year. They will be held at 16h00 (UTC+2) (10h00 EST- UTC-4) generally on Thursday of the 3rd or 4th week of the month). An expert will discuss an important topic related to asthma and co-morbid conditions.

Free registration for InterAsma members (Become a member now)

Registration for non-members: € 40 https://interasma.org/2020-2021-interasma-webinars-registration/

Webinars

24 September 2020 Pr Louis-P. Boulet: Overview of GINA 2020

29 October 2020 Dr Daniel J Jackson: Update on COVID, asthma and related diseases

26 November 2020 Dr Lawrence DuBuske: Eosinophilic Asthma

17 December 2020 Pr Jean Bousquet: Treatment of rhinitis – the ARIA program

21 January 2021 Pr Paul O’Byrne: Management of mild asthma

25 February 2001 Pr G. Walter Canonica: Update on severe asthma – new developments

25 March 2021 Pr Pascal Chanez: Inhaled and oral corticosteroids in asthma

22 April 2021 Pr Jonathan Bernstein: Environmental and workplace influences on asthma

27 May 2021 Pr Fulvio Braido: Perception of severe asthma and its treatment by Clinicians

Future conferences:
Pr Ignacio Ansotegui Allergy and airways- evaluation and treatments

Pr Carlos Nunes Epidemiology of asthma: global prevalence and consequences


https://interasma.org/2020-2021-interasma-webinars-registration/

August 19, 2020

Alert: World Allergy Organization Journal New Articles available on ScienceDirect

Alert: World Allergy Organization Journal

New Articles available on ScienceDirect

Cover Image World Allergy Organization Journal

World Allergy Organization Journal

Volume 13, Issue 7 , July 2020

Diagnosis and management of nonallergic rhinitis with eosinophilia syndrome using cystatin SN together with symptoms

Article Number 100134

Yifan Meng, Bing Yan, Yang Wang, Di Wu, Luo Zhang, Chengshuo Wang

Year-long trends of airborne pollen in Argentina: More research is needed

Article Number 100135

German D. Ramon, Emanuel Vanegas, Miguel Felix, Laura B. Barrionuevo, Adrian M. Kahn, Mariana Bertone, Maria Sol Reyes, Solange Gaviot, Cecilia Ottaviano, Ivan Cherrez-Ojeda

Food-dependent exercise-induced anaphylaxis to soybean: Gly m 5 and Gly m 6 as causative allergen components

Article Number 100439

Miyuki Hayashi, Ruby Pawankar, Shingo Yamanishi, Yasuhiko Itoh

Beliefs and preferences regarding biological treatments for severe asthma

Article Number 100441

Andras Bikov, Ipek Kivilcim Oğuzülgen, Ilaria Baiardini, Marco Contoli, Alexander Emelyanov, Omar Fassio, Juan Carlos Ivancevich, Igor Kaidashev, Krzysztof Kowal, Marina Labor, Lies Lahousse, Stefan Mihaicuta, Silviya Novakova, Alicia Padilla Galo, Alexander Simidchiev, Angelica Tiotiu, Ignacio J. Ansotegui, Jonathan A. Bernstein, Louis Philippe Boulet, Giorgio Walter Canonica

Contact dermatitis: Clinical practice findings from a single tertiary referral hospital, a 4-Year retrospective study

Article Number 100440

Giovanni Sedó-Mejía, Andrés Soto-Rodríguez, Caridad Pino-García, Alfredo Sanabria-Castro, Olga Patricia Monge-Ortega

The spectrum of primary immunodeficiencies at a tertiary care hospital in Pakistan

Article Number 100133

Sonia Qureshi, Fatima Mir, Samina Junejo, Khalid Saleem, Samreen Zaidi, Abdullah B. Naveed, Khalil Ahmad, Farah Naz Qamar

An appraisal of allergic disorders in India and an urgent call for action

Article Number 100446

Mamidipudi Thirumala Krishna, Padukudru Anand Mahesh, Pudupakkam Vedanthan, Saibal Moitra, Vinay Mehta, Devasahayam Jesudas Christopher

Read the full issue on ScienceDirect

August 5, 2020

Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review

Abstract

Background

Current guidelines do not recommend performing aeroallergen skin prick testing (SPT) in chronic spontaneous urticaria (CSU).

Objective

The objective of this review was to investigate the presence of aeroallergen sensitization and markers of T2 inflammation in subjects with CSU.

July 31, 2020

Exposure to Toxocara spp. and Ascaris lumbricoides infections and risk of allergic rhinitis in children

Abstract

Background

Substantial experimental studies suggest a role for helminthes infections in the pathogenesis of allergies, but epidemiologic data have been inconsistent. Unlike to asthma, the association between helminthes infection and allergic rhinitis (AR) has been poorly studied. Therefore, we sought to evaluate the association between exposure to Ascaris and Toxocara infections and AR.

July 30, 2020

Allergen exposure chambers: implementation in clinical trials in allergen immunotherapy

Abstract

Vienna challenge chamber

Allergen exposure chambers (AECs) have been developed for controlled allergen challenges of allergic patients mimicking natural exposure. As such, these facilities have been utilized e.g., for proof of concept, dose finding or the demonstration of onset of action and treatment effect sizes of antiallergic medication. Moreover, clinical effects of and immunological mechanisms in allergen immunotherapy (AIT) have been investigated in AECs. In Europe AIT products have to fulfill regulatory requirements for obtaining market authorization through Phase I to III clinical trials. Multiple Phase II (dose-range-finding or proof-of-concept) trials on AIT products have been performed in AECs. However, they are not accepted by regulatory bodies for pivotal (Phase III) trials and a more thorough technical and clinical validation is requested. Recently, a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI) has outlined unmet needs in further development of AECs. The following review aims to address some of these needs on the basis of recently published data in the first part, whereas the second part overviews published examples of most relevant Phase II trials in AIT performed in AEC facilities.

July 13, 2020

The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19

  • Letter to the Editor
  • Open Access

Abstract

Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conducted in different settings.

July 6, 2020

Distinct type 2-high inflammation associated molecular signatures of chronic rhinosinusitis with nasal polyps with comorbid asthma

  • Research
  • Open Access

Abstract
Background
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma have more severe disease and are difficult to treat. However, the molecular endotypes associated with CRSwNP with comorbid asthma (CRSwNP + AS) are not clear. This study aimed to investigate the characteristics of type 2 inflammation and the molecular signatures associated with CRSwNP + AS.
Methods
A total of 195 subjects; including 65 CRSwNP + AS patients, 99 CRSwNP-alone patients, and 31 healthy control subjects; were enrolled in the study. Nasal tissues from patients with CRSwNP + AS, CRSwNP-alone and control subjects were assessed for infiltration of inflammatory cells and concentrations of total IgE. Whole-transcriptome sequencing was performed and differentially expressed (DE) mRNAs and long non-coding RNAs (lncRNAs) and their associated pathways were analyzed. The correlations between type 2 cytokines and local eosinophils, tissue IgE, and transcriptome signatures were evaluated.
Results
Differentially expressed genes and pathways between CRSwNP + AS
and CRSwNP-alone. a Volcano plots illustrating DE-mRNAs of
CRSwNP + AS versus CRSwNP-alone identified by RNA sequencing.
b Top 15 KEGG pathways (blue column) and top 5 BioCarta pathways
(turquoise column) significantly enriched by DE-mRNAs.
c The expression of arachidonic acid metabolism-related DE-mRNAs
between CRSwNP + AS and CRSwNP-alone.
The colour coding of heat maps represents the gene expression
level normalized to Control group, calculated based on fragments
per kilo-base of exon per million fragments mapped (FPKM).
Yellow box indicates the up-regulated genes in CRSwNP + AS group.
d The expression of critical cytokines and their receptors that indicated
the activity of different inflammatory endotypes.
Yellow stars represent significantly differentially expressed
genes between CRSwNP + AS and CRSwNP-alone.
P < 0.05 were considered statistically significant. CRSwNP chronic rhinosinusitis
with nasal polyps, AS asthma, DE differentially expressed,
KEGG Kyoto Encyclopedia of Genes and Genomes

Significantly higher local eosinophil infiltration and higher levels of total IgE were found in nasal tissues from CRSwNP + AS patients than in nasal tissues from CRSwNP-alone patients. Furthermore, atopy and recurrence were significantly more frequent in patients with CRSwNP + AS than in patients with CRSwNP-alone (62.5% vs 28.6% and 66.7% vs 26.9%, respectively). RNA sequencing analysis identified 1988 common DE-mRNAs, and 176 common DE-lncRNAs shared by CRSwNP + AS versus control and CRSwNP-alone versus control. Weighted gene coexpression network analysis (WGCNA) identified LINC01146 as hub lncRNA dysregulated in both subtypes of CRSwNP. Overall, 968 DE-mRNAs and 312 DE-lncRNAs were identified between CRSwNP + AS and CRSwNP-alone. Both pathway enrichment analysis and WGCNA indicated that the phenotypic traits of CRSwNP + AS were mainly associated with higher activities of arachidonic acid metabolism, type 2 cytokines related pathway and fibrinolysis pathway, and lower activity of IL-17 signalling pathway. Furthermore, the expression of type 2 cytokines; IL5 and IL13, was positively correlated with local eosinophil infiltration, tissue IgE level, and the expression of DE-mRNAs that related to arachidonic acid metabolism. Moreover, WGCNA identified HK3-006 as hub lncRNA in yellow module that most positively correlated with phenotypic traits of CRSwNP + AS.
Conclusions
Patients with CRSwNP + AS have distinct type 2-high inflammation-associated molecular signatures in nasal tissues compared to patients with CRSwNP-alone.